Ernexa Therapeutics Inc. (ERNA) EBIT Margin (2010 - 2024)
Ernexa Therapeutics' (ERNA) quarterly EBIT Margin came in at 14194.74% in Q4 2024, down 242943.0% YoY from N/an in Q1 2024, and down 2960.13% on a QoQ basis from 463.86% in Q3 2024.
Ernexa Therapeutics Inc. (ERNA) EBIT Margin (2010 - 2024) Analysis & Trends
Ernexa Therapeutics (ERNA) has 13 years of EBIT Margin data on file, last reported at 14194.74% in Q4 2024.
- Quarterly EBIT Margin fell 242943.0% year-over-year to 14194.74% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 2612.33% (up 1852267.0% YoY) and the FY2024 annual result came in at 2612.33%, up 1852267.0% from the prior year.
- EBIT Margin retreated to 14194.74% in Q4 2024, from 463.86% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 42.38% in Q1 2020 to a low of 14194.74% in Q4 2024.
- A 3-year average of 6709.82% and a median of 10491.49% in 2024 frame the typical range for EBIT Margin.
- The widest YoY moves for EBIT Margin: up 1033026 bps in 2024, down 242943 bps in 2024.
- Tracing ERNA's EBIT Margin over 3 years: stood at 187.8% in 2020, then plunged by 6165 bps to 11765.31% in 2023, then fell by 21 bps to 14194.74% in 2024.
- The last three EBIT Margin figures came in at 14194.74% (Q4 2024), 463.86% (Q3 2024), and 10491.49% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -14,194.74% |
| Sep 30, 2024 | -463.86% |
| Jun 30, 2024 | -10,491.49% |
| Mar 31, 2024 | -12,312.77% |
| Dec 31, 2023 | -11,765.31% |
| Sep 30, 2023 | -10,794.12% |
| Dec 31, 2020 | -187.80% |
| Sep 30, 2020 | -135.92% |
| Mar 31, 2020 | -42.38% |
| Dec 31, 2019 | -23.74% |
| Sep 30, 2019 | -6.90% |
| Jun 30, 2019 | -0.04% |
| Mar 31, 2019 | -4.49% |
| Dec 31, 2018 | 2.92% |
| Sep 30, 2018 | 6.16% |
| Jun 30, 2018 | -0.48% |
| Mar 31, 2018 | -5.43% |
| Dec 31, 2017 | -9.23% |
| Sep 30, 2017 | -1.02% |
| Jun 30, 2017 | -0.47% |